Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Press release

Transgene Announces Participation at Upcoming Investor Events

20160302 March April 2016 IR events ENG

Published 2 March 2016
Categorized as 2016, Press release

Transgene and ABL Announce the Acquisition by ABL Europe of Transgene’s Production Asset

20160203 PR ABL TG SYMPHONY

Published 3 February 2016
Categorized as 2016, Press release

EIB lends EUR 20m to Transgene

20160128 PR transgene BEI final version

Published 28 January 2016
Categorized as 2016, Press release

Transgene Announces Financial Calendar for 2016

20160108 financial calendar_EN ver 1

Published 8 January 2016
Categorized as 2016, Press release

Transgene enters new phase in its strategic development

20160107 Strategic update ENG clean

Published 7 January 2016
Categorized as 2016, Press release

Transgene Announces First Patient Randomized in Multinational Phase 3 Trial for Pexa-Vec Oncolytic Immunotherapy in Advanced Liver Cancer

20160106 Ph 3 pexa vec in HCC trial initiation VER8

Published 6 January 2016
Categorized as 2016, Pexa-Vec, Press release

Transgene Announces Publication in “The Lancet Oncology” of Phase 2b TIME Trial Results with TG4010 Immunotherapy in Non-Small Cell Lung Cancer

20151223_TIME Ph2b Lancet Oncology 2015_PR EN

Published 23 December 2015
Categorized as 2015, Press release, TG4010

Transgene and SillaJen Announce Revised Agreement for Pexa-Vec Oncolytic Viral Therapy and Provide Update on Clinical Development

20151112 SillaJen_Pexavec_Joint

Published 12 November 2015
Categorized as 2015, Pexa-Vec, Press release

Transgene Announces Dosing of First Patient with TG1050 for Treatment of Chronic Hepatitis B Infection

20151103 TG1050 FINAL VERSION US

Published 4 November 2015
Categorized as 2015, Press release, TG1050

Transgene Reports Third Quarter 2015 Financial Results

20151021 PR US Q3 2015 FINAL

Published 21 October 2015
Categorized as 2015, Press release

Posts pagination

Newer posts Page 1 … Page 31 … Page 33 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu